ppi-2458
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00100347)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Methionine aminopeptidase 2INHIBITOR
METAP2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@@H]1[C@H](OC(=O)N[C@@H](C(N)=O)C(C)C)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C- Mol. weight
- 424.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3527358 ↗
Also known as
- ppi2458
- ppi 2458
- ppi-2458
- ppi-2458
- ppi-2458
- ppi-2458
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00100347 | Phase 1 | Dec 1, 2004 | Harvard University, Praecis Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Praecis Pharmaceuticals | For profit | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1